Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 202158 (selepressin) as primary vasopressor in early septic shock
2012-001254-26Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selepressin in septic shock and Vasodilatory shock, sponsored by Ferring Pharmaceuticals. Primary endpoint: Stabilisation of blood pressure. Started May 2012; status: completed.
02
Drugs
selepressin
03
Conditions
septic shockVasodilatory shock
Beyond the preview
Go deeper on 2012-001254-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001254-26.